Fungal Infections During and After the SARS-CoV-2 Pandemic: A Retrospective Comparison

NCT06483815 | Enrolling By Invitation

• 1 other identifier: ODFUNGAL
• Study Type: observational
• Target: 1,441
• Locations: 1 country
• Sites: 1

Brief Summary

his study aims to retrospectively compare fungal positivity rates between the SARS-CoV-2 pandemic and the post-pandemic periods. During the pandemic, Candida species had a positivity rate of 17.36%, and Aspergillus had a rate of 2.22%. Post-pandemic, these rates decreased to 9.29% and 1.00%, respectively. The overall fungal positivity rate decreased from 9.15% during the pandemic to 5.13% post-pandemic. Statistical analysis revealed a significant decrease in fungal positivity rates post-pandemic (p \< 0.01). These findings underscore the effectiveness of post-pandemic healthcare interventions and infection control strategies.

Conditions

Fungal Infections

Keywords

fungal infections, SARS-CoV-2, pandemic, post-pandemic

Outcome Measures

Primary Outcomes (1)

• Fungal positivity rates during the SARS-CoV-2 pandemic period and post-pandemic period

  Fungal infection data from samples of patients, 623 of whom were during the SARS-CoV-2 epidemic and 818 of whom were in the post-epidemic period, were retrospectively examined. Fungal positivity rates for different fungal agents such as Candida species and Aspergillus were calculated separately and compared statistically.

  2020-2024

Study Arms (1)

The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period

The study was conducted retrospectively, analyzing a total of 1441 patients. Among these, 623 were during the SARS-CoV-2 pandemic and 818 were in the post-pandemic period. Fungal positivity rates were calculated separately for different fungal agents including Candida species and Aspergillus. These rates were presented as percentages and statistically compared between the two periods.

Diagnostic Test: Culture, İsolation

Interventions

Culture, İsolation DIAGNOSTIC_TEST

Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.

The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients diagnosed with pneumonia according to clinical, laboratory and radiological data in the chest diseases, infectious diseases and intensive care unit of Hisar HIntercontinental Hospital

You may qualify if:

• Patients over 18 years of age of both genders

You may not qualify if:

• Patients under 18 years of age,
• Patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization

Sponsors & Collaborators

• Bekir Sami Uyanık: lead

Study Sites (1)

Hisar Hospital Intercontinental

Istanbul, 34768, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

bronchoalveolar lavage, tracheal aspirate, sputum

MeSH Terms

Conditions

Mycoses

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Study Officials

• Ramazan Gözüküçük

  Hisar Hospital Responsible Manager

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 29, 2024
• First Posted: July 3, 2024
• Study Start: June 1, 2024
• Primary Completion: July 20, 2024
• Study Completion: July 30, 2024
• Last Updated: July 5, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)